Medicago, GSK start phase III of COVID-19 vaccine trial

By The Science Advisory Board staff writers

March 16, 2021 -- Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.

This portion of the trial will enroll 30,000 volunteers from 10 countries, according to the two firms. The vaccine candidate uses coronavirus-like-particle technology; two doses of 3.75 µg are administered three weeks apart. The drug has been granted "fast track" designation by the U.S. Food and Drug Administration (FDA).

Medicago has also begun a feasibility study of a vaccine candidate for emerging COVID-19 variants, it said.

Medicago, GSK begin phase II/III trial of adjuvanted COVID-19 vaccine
Medicago and GlaxoSmithKline (GSK) have begun a phase II/III clinical trial of their plant-derived COVID-19 vaccine candidate.
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...
Sanofi, GSK begin clinical trial for COVID-19 vaccine
Sanofi and GlaxoSmithKline (GSK) have started the phase I/II clinical trial for an adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Sanofi, GSK get $2.1B for COVID-19 vaccine
The U.S. government will provide up to $2.1 billion to Sanofi and GlaxoSmithKline (GSK) for the development and manufacturing of a recombinant protein-based...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter